Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Net Cash Flow: 2011-2024

Historic Net Cash Flow for Ptc Therapeutics (PTCT) over the last 14 years, with Dec 2024 value amounting to $192.4 million.

  • Ptc Therapeutics' Net Cash Flow fell 148.16% to -$340.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $142.2 million, marking a year-over-year decrease of 59.81%. This contributed to the annual value of $192.4 million for FY2024, which is 38.20% down from last year.
  • Per Ptc Therapeutics' latest filing, its Net Cash Flow stood at $192.4 million for FY2024, which was down 38.20% from $311.2 million recorded in FY2023.
  • In the past 5 years, Ptc Therapeutics' Net Cash Flow registered a high of $311.2 million during FY2023, and its lowest value of -$86.9 million during FY2020.
  • Moreover, its 3-year median value for Net Cash Flow was $192.4 million (2024), whereas its average is $201.7 million.
  • In the last 5 years, Ptc Therapeutics' Net Cash Flow crashed by 168.25% in 2020 and then surged by 1,000.20% in 2022.
  • Ptc Therapeutics' Net Cash Flow (Yearly) stood at -$86.9 million in 2020, then soared by 87.03% to -$11.3 million in 2021, then skyrocketed by 1,000.20% to $101.5 million in 2022, then spiked by 206.71% to $311.2 million in 2023, then crashed by 38.20% to $192.4 million in 2024.